Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Alkixen is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Recommended Dose: 250 mg orally, twice daily Geriatric Use: No differences in safety or efficacy were observed between older and younger patients. Clinical studies of Crizotinib in patients with ROS1-positive metastatic NSCLC did not include sufficient numbers of patients age 65 years and older to determine whether they respond differently from younger patientsPediatric Dose: The safety and effectiveness of Crizotinib in pediatric patients have not been established.Renal impairment: 250 mg orally, once daily in patients with severe renal impairment (creatinine clearance <30 mL/min) not requiring dialysis. No starting dose adjustment is needed for patients with mild (ClCr 60-89 mL/min) or moderate (ClCr 30-59 mL/min) renal impairment based on a population pharmacokinetic analysis.Hepatic Impairment: Caution should be used in patients with hepatic impairment
Side Effects
The most common adverse reactions (≥25%) are vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, and neuropathy.
Cautions & Contraindications
Warnings & Precautions
Hepatotoxicity: Patients should undergo periodic liver testing. Crizocent should be temporarily suspended, dose reduced or permanently suspendedInterstitial lung disease (ILD)/ Pneumonitis: Drug should be permanently discontinued in patients with ILD/ PneumonitisQT interval prolongation: Electrocardiograms and electrolytes in patients who have a history of or predisposition for QTc prolongation, or who are taking medications that prolong QT should be monitored. Crizocent should be temporarily suspended, dose reduced or permanently suspendedBradycardia: Crizocent can cause bradycardia. Heart rate and blood pressure should be regularly monitored. Crizocent should be temporarily suspended, dose reduced or permanently suspendedSevere visual loss: Ophthalmological evaluation should be performed. Crizocent should be discontinued in severe visual lossEmbryo-fetal toxicity: Crizocent can cause fetal harm. Females of reproductive potential should be advised of the potential risk to a fetus and use of effective contraception